Embecta Dividend Insights: Key Details Ahead of Ex-Dividend Date May 28, 2025
Generated by AI AgentAinvest Dividend Digest
Saturday, May 24, 2025 7:02 pm ET1min read
EMBC--
Embecta Corporation has announced a dividend of $0.15 per share, consistent with the average of its last ten dividends. The dividend was declared on May 5, 2025, with an ex-dividend date set for May 28, 2025, and will be paid out on Jun 13, 2025. The last dividend issued by EmbectaEMBC-- was on Mar 14, 2025, also amounting to $0.15 per share. This dividend, like the previous one, is a cash dividend.
Recently, Embecta has outlined a strategic shift from its core business of insulin delivery to broader medical applications. Dev Kurdikar, the CEO, emphasized the company's plans to maintain leadership in insulin injection while expanding into new medical supplies. Embecta revealed its long-term vision during its inaugural Analyst and Investor Day on May 22, 2025, showcasing a phased approach for sustainable growth. As of late, Director David Melcher made a significant purchase of 10,000 shares of Embecta stock on May 23, 2025, totaling over $105,995, indicating confidence in the company's trajectory. Meanwhile, analyst Marie Thibault adjusted Embecta’s stock price target from $26 to $25 on May 24, 2025, due to margin considerations, while still maintaining a Buy rating.
Over the past week, Embecta has reaffirmed its fiscal year 2025 financial guidance, projecting revenues between $1,073 million and $1,090 million, with adjusted operating margins of 29.75% to 30.75%. The company aims to strengthen its core business, expand its product portfolio, and enhance financial flexibility. Embecta’s long range financial plan through 2028 anticipates maintaining a stable revenue CAGR, achieving an adjusted operating margin of 28% to 30%, and repaying $450 million to $500 million of debt.
In conclusion, Embecta is strategically transitioning to broaden its medical applications while maintaining its core insulin delivery business. Investors should note that the ex-dividend date is May 28, 2025, marking the last opportunity to purchase shares and qualify for the upcoming dividend payout. Purchases made after this date will not be eligible for the dividend.
Recently, Embecta has outlined a strategic shift from its core business of insulin delivery to broader medical applications. Dev Kurdikar, the CEO, emphasized the company's plans to maintain leadership in insulin injection while expanding into new medical supplies. Embecta revealed its long-term vision during its inaugural Analyst and Investor Day on May 22, 2025, showcasing a phased approach for sustainable growth. As of late, Director David Melcher made a significant purchase of 10,000 shares of Embecta stock on May 23, 2025, totaling over $105,995, indicating confidence in the company's trajectory. Meanwhile, analyst Marie Thibault adjusted Embecta’s stock price target from $26 to $25 on May 24, 2025, due to margin considerations, while still maintaining a Buy rating.
Over the past week, Embecta has reaffirmed its fiscal year 2025 financial guidance, projecting revenues between $1,073 million and $1,090 million, with adjusted operating margins of 29.75% to 30.75%. The company aims to strengthen its core business, expand its product portfolio, and enhance financial flexibility. Embecta’s long range financial plan through 2028 anticipates maintaining a stable revenue CAGR, achieving an adjusted operating margin of 28% to 30%, and repaying $450 million to $500 million of debt.
In conclusion, Embecta is strategically transitioning to broaden its medical applications while maintaining its core insulin delivery business. Investors should note that the ex-dividend date is May 28, 2025, marking the last opportunity to purchase shares and qualify for the upcoming dividend payout. Purchases made after this date will not be eligible for the dividend.
Sip from the stream of US stock dividends. Your income play.
Latest Articles
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue

Comments
No comments yet